Reply

Am J Ophthalmol. 2017 Feb:174:182-183. doi: 10.1016/j.ajo.2016.11.008. Epub 2016 Dec 7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Macular Degeneration*
  • Ranibizumab
  • Receptors, Vascular Endothelial Growth Factor*
  • Recombinant Fusion Proteins
  • Retreatment

Substances

  • Recombinant Fusion Proteins
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab